Birnam Oak Advisors LP Makes New $15.83 Million Investment in Amedisys, Inc. (NASDAQ:AMED)

Birnam Oak Advisors LP purchased a new stake in Amedisys, Inc. (NASDAQ:AMED - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 174,383 shares of the health services provider's stock, valued at approximately $15,832,000. Amedisys comprises about 7.7% of Birnam Oak Advisors LP's investment portfolio, making the stock its 6th largest position. Birnam Oak Advisors LP owned 0.53% of Amedisys as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Crossmark Global Holdings Inc. acquired a new position in Amedisys during the third quarter worth approximately $243,000. State of New Jersey Common Pension Fund D increased its holdings in shares of Amedisys by 1.7% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 20,357 shares of the health services provider's stock valued at $1,965,000 after acquiring an additional 339 shares during the period. KBC Group NV purchased a new stake in Amedisys in the 3rd quarter valued at $63,000. Amara Financial LLC. acquired a new stake in Amedisys during the 3rd quarter worth $526,000. Finally, Charles Schwab Investment Management Inc. grew its position in Amedisys by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider's stock worth $33,400,000 after purchasing an additional 9,004 shares during the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Price Performance

AMED stock traded down $0.39 during trading on Friday, reaching $92.38. 1,536,807 shares of the company were exchanged, compared to its average volume of 380,706. The stock's 50 day moving average price is $92.20 and its 200 day moving average price is $92.67. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The company has a market cap of $3.03 billion, a P/E ratio of 36.66, a PEG ratio of 1.78 and a beta of 0.76.

Remove Ads

Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. As a group, analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.